Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin.

Slides:

Advertisements

Similar presentations

Pharmacotherapy Oral Hypoglycemic Agents (OHA) Antihyperglycemic agents Used only in type 2 diabetes, with diet and exercise CDA Clinical Practice Guidelines.

Advertisements

The efficacy of ‘Basal supported Oral Therapy ’ with ‘Sitagliptin’ in Japanese type 2 diabetes patients: Yoshihiko Suzuki HDC Atlas Clinic,

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.

Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada Canadian Diabetes Association 2003.

LONG TERM BENEFITS OF ORAL AGENTS

Effect of 21-day Holistic Therapy at “Our Native Village Eco Resorts” on Diabetes Mellitus as assessed by blood glucose levels and consumption of oral.

Philip J. Barter, et al. Circulation 2011;124:

Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.

Insulin Initiation and Titration for Family Physicians: Case Study #2: Andy Alice Y.Y. Cheng, MD FRCPC Peter Lin, MD CCFP.

Patient-directed titration to achieve glycaemic goals in type 2 diabetes using once-daily basal insulin: results of the TITRATE randomized controlled trial.

Epidemiology and Diagnosis A Practical Guide to Therapy Monotherapy Combination Therapy Add ons.

Sglt-2 insulin Matthews D, Fulcher G, Perkovic V, et al. Ef  cacy and safety of canagliflozin,an inhibitor of sodium glucose co-transporter 2, added.

Insulin Elixir of life Dr. Sergio Diez Alvarez Staff Specialist Physician.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

Date of download: 7/5/2016 From: Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes:

Fig. 1. Study flow chart. Group A: intensifying oral hypoglycemic agents (OHAs; sulfonylurea+metformin dose titration or fixed-dose combination added to.

Basal Insulin Initiation in Elderly Patients with Type 2 Diabetes in Taiwan: A Comparison with Younger Patients Ming-Nan Chien, Chun-Chuan Lee, Sung-Chen.

Anesthes. 2008;108(3): doi: /ALN.0b013e Figure Legend:

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2005 American Medical Association. All rights reserved.

From: United Kingdom Prospective Diabetes Study 24: A 6-Year, Randomized, Controlled Trial Comparing Sulfonylurea, Insulin, and Metformin Therapy in Patients.

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

Neal B, et al. Diabetes Care 2015;38:403–411

WHAT IS THE REAL NORMAL RANGE?

Placebo Metformin ***p < vs placebo

Hepatic glucose production as a function of fasting plasma glucose levels. These studies involved the same individuals who were studied in Fig

From: United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications.

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Applying Data to Practice

MK-0431 P051 PDT APPROVED 4/10/09 11/13/2018 2:49 PM

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

New Patient-Friendly Options for Managing Insulin Dosing

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

Jean L. Chan, MD, Martin J. Abrahamson, MD Mayo Clinic Proceedings

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Sequential insulin strategies in type 2 diabetes.

Athena Philis-Tsimikas, MD The American Journal of Medicine

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Insulin Use in Primary Care: Practice Challenges

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Gerry H. Tan, M.D., Roger L. Nelson, M.D. Mayo Clinic Proceedings

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Approach to starting and adjusting insulin in type 2 diabetes.

Advancements in Glucose Monitoring

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Receiver operating characteristic analyses showing area under the curves with reference to 2-hour OGTT (A,B) and fasting plasma glucose (C,D). HbA1c, glycated.

Schematic of screening program for diabetes mellitus (DM) during acute myocardial infarction (AMI). Schematic of screening program for diabetes mellitus.

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Comparison of receiver operating characteristic (ROC) curves for predicting oral glucose tolerance test (OGTT) 1 h postload glucose ≥155 mg/dL in (A) patients.

Fig. 3. (A) Least-squares (LS) mean difference in glycosylated hemoglobin (HbA1c) from baseline, and (B) LS mean difference in HbA1c from baseline over.

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.

Fig. 2. Changes in glycosylated hemoglobin (HbA1c) levels

Time course of HbA1c (A), FPG (B), body weight (C), SMPG (D), and lipase (E) from week 0 to week 26. Time course of HbA1c (A), FPG (B), body weight (C),

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Insulin in Type 2 Diabetes

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

© The Author(s) Published by Science and Education Publishing.

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Fresh perspectives ON BASAL Insulins in diabetes care

Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.

Presentation transcript:

Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin dose titration or fixed-dose combination added to other OHAs). Group B: basal insulin alone or added to OHA mono/combination therapy. Group C: basal insulin plus rapid acting insulin combination therapy alone or added to OHA mono/combination therapy. P value was calculated by analysis of covariance with adjustment of baseline HbA1c. Fig. 2. Change in (A) glycosylated hemoglobin (HbA1c) and (B) fasting plasma glucose (FPG). Group A: oral hypoglycemic agents (OHAs; sulfonylurea+metformin dose titration or fixed-dose combination added to other OHAs). Group B: basal insulin alone or added to OHA mono/combination therapy. Group C: basal insulin plus rapid acting insulin combination… Diabetes Metab J. 2017 Jun;41(3):170-178. https://doi.org/10.4093/dmj.2017.41.3.170